5 results
The primary objective is:* To determine the overall response rate (ORR) of 4 weekly infusions of obinutuzumab monotherapy (Induction I) in patients with rituximab-refractory follicular lymphoma.The secondary objectives are:* To determine theā¦
The primary objective of the PASSENGER study is to investigate any relationship between changes in SonR1 augmentation and a change in patients* exercise capacity as assessed by the 6 Minute Walk Test.
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
To evaluate the safety and efficacy of PRX-102 in patients with Fabry disease currently treated with agalsidase alfa
To evaluate the ongoing safety, tolerability, and efficacy parameters of pegunigalsidase alfa in adult Fabry patients who have successfully completed studies PB-102-F20 and PB-102-F30, or completed at least 48 months in study PB-102-F03.